Replies to post #211291 on Biotech Values

[jbog]

I think Thermo's expertise and capital will propel Patheon to being equal to or exceeding that of the industry leader Lonza.

All around good move, but a little early in my view.

[DewDiligence]

PRXL taken private at $88.10/sh in cash—a 28% premium to the closing price on 5/5/17 (the day before the WSJ reported buyout discussions):

https://finance.yahoo.com/news/parexel-international-enters-definitive-agreement-110500275.html

Consolidation in the CRO/CMO/CDMO industry continues. The buyer is Pamplona Capital Management, a global private-equity firm. The nominal deal value is $4.6B.